- MacroGenics Inc MGNX announced preliminary safety and anti-tumor activity data from the dose expansion phase of its ongoing Phase 1 trial of lorigerlimab.
- As of December 12, 2022, data cut-off, 118 patients with mCRPC, melanoma, non-small cell lung cancer, or microsatellite-stable colorectal cancer were enrolled.
- The results demonstrated a manageable overall safety profile. Treatment-related AEs (TRAEs) occurred in 86.6% of patients. AEs resulted in treatment discontinuation in 24.4% of patients. There were no fatal AEs related to lorigerlimab.
- Also Read: MacroGenics Shares Jump On Gilead Licensing Pact For Blood Cancer Candidates.
- At study entry, 35 patients with mCRPC had measurable soft tissue disease.
- Nine of the 35 patients (25.7%) achieved confirmed partial responses (cPR). The median duration of response for these nine patients was 4.6 months, with four patients remaining on lorigerlimab as of the data cut-off.
- Among the other five patients who had achieved cPR, four discontinued due to unrelated adverse events, and one discontinued due to a physician’s decision.
- Twelve of 42 patients (28.6%) in the metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction, including 9 (21.4%) who achieved ≥ 90% PSA reduction.
- Price Action: MGNX shares are down 8.66% at $5.50 on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
